Amyloid-beta PET Imaging With 18F-92 in Alzheimer's Disease

  • STATUS
    Recruiting
  • End date
    Jul 1, 2024
  • participants needed
    50
  • sponsor
    First Affiliated Hospital of Fujian Medical University
Updated on 24 January 2022
alzheimer's disease
amyloid
memory impairment
Accepts healthy volunteers

Summary

Alzheimer's disease is a neurodegenerative disease. Numerous studies have reported that β-amyloid (Aβ) is an important marker for the diagnosis of AD. 18F-92 molecular probe is a novel molecularly targeted imaging agent, which can rapidly penetrate the blood-brain barrier and has high affinity and selectivity for Aβ protein. In this study, 18F-92 PET/CT was used to monitor the regional distribution and the degree of deposition in patients with Alzheimer's disease, and compared with clinical symptoms (neuropsychometry) to evaluate its application value in the diagnosis of AD.

Description

Healthy volunteers as well as patients meeting Alzheimer's criteria will be recruited for this study.

We will use PET/CT imaging technology to scan each participant's whole body or head and collect image data for analysis to evaluate the distribution and metabolism of 18F-92 in the subject's body. Time from drug injection to scan completion is approximately 1 hour.

Details
Condition Alzheimer's Disease
Treatment 18F-92
Clinical Study IdentifierNCT04926272
SponsorFirst Affiliated Hospital of Fujian Medical University
Last Modified on24 January 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients or their families complain of significant memory impairment
Objective memory impairment (e.g., tests of article identification, recall, delayed memory)
Meets Alzheimer's criteria for DSMIV and NINCDS-ADRDA
Be able to obtain complete diagnosis and treatment records and be able to carry out long-term follow-up
Signed written consent

Exclusion Criteria

Nervous system diseases: including brain tumors, craniocerebral trauma, multiple sclerosis, epilepsy, etc
Psychiatric disorders: including anxiety disorder, affective disorder, severe psychosis, or drug-induced psychosis
Pregnancy or lactation
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note